Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis.
Isoniazid
Mycobacterium tuberculosis
PCR
Rifampin
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
14
08
2023
accepted:
29
09
2023
medline:
27
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Isoniazid and rifampin are the first -line drugs against Mycobacterium tuberculosis. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs. In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain. of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%. In our study, the prevalence of resistance to isoniazid and rifampin among Mycobacterium tuberculosis complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Isoniazid and rifampin are the first -line drugs against Mycobacterium tuberculosis. Resistance to these important drugs is a serious threat to human public health. Therefore, this study aimed at molecular detection of resistance to these valuable drugs.
MATERIALS AND METHODS
METHODS
In this descriptive cross-sectional study, 111 non - duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to the Ardabil Health Center between 2017 and 2020. The samples were first examined by microscopic method, then their DNA was extracted using the boiling method. Specific primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identification of MDR strain.
RESULTS
RESULTS
of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%.
CONCLUSION
CONCLUSIONS
In our study, the prevalence of resistance to isoniazid and rifampin among Mycobacterium tuberculosis complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti- tuberculosis resistance rate among NTM compared to MTC strains.
Identifiants
pubmed: 37971566
doi: 10.1007/s11033-023-08867-7
pii: 10.1007/s11033-023-08867-7
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10271-10275Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Bennett JE, Dolin R, Blaser MJ (2019) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases E-Book: 2-Volume Set. Elsevier health sciences
Organization WH (2022) Rapid communication: key changes to the treatment of drug-resistant tuberculosis. World Health Organization
Organization WH (2021) Rapid communication on updated guidance on the management of tuberculosis in children and adolescents.
Tiberi S, Utjesanovic N, Galvin J, Centis R, D’Ambrosio L, van den Boom M et al (2022) Drug resistant TB–latest developments in epidemiology, diagnostics and management. Int J Infect Dis 124:S20–S5
doi: 10.1016/j.ijid.2022.03.026
pubmed: 35342000
Xi Y, Zhang W, Qiao R-J, Tang J (2022) Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis. PLoS ONE 17(6):e0270003
doi: 10.1371/journal.pone.0270003
pubmed: 35709161
pmcid: 9202901
Sultana ZZ, Hoque FU, Beyene J, Akhlak-Ul-Islam M, Khan MHR, Ahmed S et al (2021) HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 21(1):1–13
Qader GQ, Seddiq MK, Rashidi KM, Manzoor L, Hamim A, Akhgar MH et al (2021) Prevalence of latent tuberculosis infection among health workers in Afghanistan: a cross-sectional study. PLoS ONE 16(6):e0252307
doi: 10.1371/journal.pone.0252307
pubmed: 34061873
pmcid: 8168887
Ali S, Khan MT, Khan AS, Mohammad N, Khan MM, Ahmad S et al (2020) Prevalence of multi-drug resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa–a high tuberculosis endemic area of Pakistan. Pol J Microbiol 69(2):133–137
doi: 10.33073/pjm-2020-005
pmcid: 7324855
Graefen B, Fazal N (2023) Quality as a driver of Progress: Tuberculosis Care in Azerbaijan. Indian J Tuberculosis.
Ashouri P, Mohammadshahi J, Nikbin VS, Peeridogaheh H, Mohammadi-Ghalehbin B, Refahi S et al (2022) Antimicrobial Resistance, Integron Carriage, and Fluoroquinolone Resistance genes in Acinetobacte baumannii isolates. Archives of Clinical Infectious Diseases. ;17(5)
Green MR, Sambrook J (2012) Molecular cloning. A Laboratory Manual 4th.
Khosravi AD, Goodarzi H, Alavi SM (2012) Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and multiplex allele-specific polymerase chain reaction. Brazilian J Infect Dis 16:57–62
Mahon CR, Lehman DC (2022) Textbook of diagnostic microbiology-e-book. Elsevier Health Sciences
Riddell SW, Sanyal S (2019) Essentials of diagnostic microbiology. Introduction to Clinical Infectious Diseases: A Problem-Based Approach. :439 – 60
Al-Mutairi NM, Ahmad S, Mokaddas EM (2019) Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB. Eur J Med Res 24:1–13
doi: 10.1186/s40001-019-0397-2
Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM et al (2015) WHO’s new end TB strategy. The Lancet 385(9979):1799–1801
doi: 10.1016/S0140-6736(15)60570-0
Kundu S, Ghosh R, National (2022) TB elimination program (NTEP): at a glance. J Association Chest Physicians 10(2):55–66
Organization WH (2022) WHO operational handbook on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. World Health Organization
Dean AS, Cox H, Zignol M (2017) Epidemiology of drug-resistant tuberculosis. Strain variation in the Mycobacterium tuberculosis complex: its role in biology, epidemiology and control. :209 – 20
Baghaei P, Tabarsi P, Dorriz D, Marjani M, Shamaei M, Pooramiri MV et al (2011) Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther 18(2):e29–e34
doi: 10.1097/MJT.0b013e3181c0806d
pubmed: 20019591
Sahebi L, Ansarin K, Farajnia S, Monfaredan A, Sabour S (2015) Prevalence and risk factors of drug-resistant tuberculosis in border provinces of Iran. Postgrad Med 127(6):600–606
doi: 10.1080/00325481.2015.1069168
pubmed: 26174471
Khademi F, Sahebkar A (2021) An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013–2020). Iran J Basic Med Sci 24(4):428
pubmed: 34094023
pmcid: 8143714
Rashedi J, Mahdavi Poor B, Rafi A, Asgharzadeh M, Abdolalizadeh J, Moaddab SR (2015) Multidrug-resistant tuberculosis in north-west of Iran and Republic of Azerbaijan: a major public health concern for iranian people. J Res Health Sci 15(2):101–103
pubmed: 26175292